Organon

Our mission is to deliver impactful medicines and solutions for a healthier every day. We reserve the right to remove any comments that reference a product.

Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. For more information, visit www.organon.com.

Commenting Guidelines:

Thank you for your interest in Organon. Providing useful and interesting content about our company and fostering open and respectful dialogue around specific topics is our ultimate goal. Organon respects the rights of individuals using social media to voice their views and opinions. However, within our social media channels, we reserve the right to remove comments that are considered inappropriate, off-topic, abusive, or being used to promote and solicit for third-party sites, initiatives or products. We ask that you please respect the following guidelines for our page:

Please refrain from mentioning Organon products or products from other companies. Comments or posts that are factually inaccurate or misleading, are spam, inappropriate, violate another’s copyright or intellectual property, use profanity or are defamatory will be deleted. There may be other circumstances that will require us to remove a comment. Organon reserves the right to delete any posting at its sole discretion. We encourage you to respect fellow community members and follow Facebook's Statements of Rights and Responsibilities. This page is intended to provide a forum for open discussion and the content provided by those other than Organon does not represent the opinions or positions of Organon. The content available on this page is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Organon recommends that you consult your healthcare provider regarding personal health matters. Privacy:

Organon may collect information about you, such as your name and/or user name and the comments you post to understand and address perspectives about our company mission, strategy, practices, developments within our business and in healthcare and for legal and regulatory purposes. For more information about Organon's privacy practices, please read our Privacy Commitment at www.organon.com/privacy.

02/05/2026

Noha Salem, Global Women’s Health Policy Lead, reflected on the past year—and what it underscored about the urgency of sustainable access to :

“While meaningful progress has been achieved, it remains fragile. Recent funding cuts to family planning programs have led to clinic closures and supply disruptions across many low‑ and middle‑income countries, leaving millions of women without the contraceptive care they need. 2025 underscored why expanding sustainable, reliable access is so critical—and why Organon’s role must extend beyond that of a manufacturer to that of a strategic partner committed to strengthening resilient health systems.

Looking ahead, our commitment is clear. In 2026, we will continue working closely with ministries of health and partner organizations to advance country‑led access models. By supporting sustainable financing approaches, we aim to reinforce the investment case for women’s health and help build a more resilient family planning ecosystem—so that every woman receives the care she needs, when she needs it."

02/02/2026

Adam Dark, Regional Commercial Lead, continues our prediction series by sharing his 2026 focus in care. His perspective highlights priorities ranging from shortening the time to diagnosis to advancing access to innovative therapies for a condition that disproportionately impacts women.

01/28/2026

In 2026, one thing is clear: sustainable access to women’s health care remains essential. We spoke with Organon leaders about the progress made, what’s ahead, and where we’re committed to going next.

Nerina Sapienza, Women’s Health, Global Fertility Commercial Lead, reflected on what’s shaping the future of fertility care—from expanding access and reimbursement globally to working to improve the patient journey and reduce stigma.

01/21/2026

From disrupted sleep to daily discomfort, the burden of chronic skin conditions is real. At Organon, our dermatology focus goes beyond symptoms—we’re investing in innovation, and working to improve access and build the support structure that patients and providers need.

Discover more about our commitment to improving outcomes for people living with chronic skin conditions: https://ogn.llc/6181QBwGF

01/17/2026

Today, Organon announced the US FDA has approved a supplemental new drug application extending the duration of use for one of our long-acting contraceptive options.

At Organon, we are committed to advancing inclusive and comprehensive women’s healthcare, including expanding access to contraception and increasing available choices.

Intended for U.S. audiences only.

12/19/2025

Recently we came together for our year-end Founders’ Forum (our unique spin on a town hall). This meeting gave us all the opportunity to reflect on the past year and the impact Organon Founders have had around the world. In these stories, we see great resilience and dedication to our mission of improving the health of people throughout their lives and advancing women’s health.

Thank you to all Founders for being part of this journey and for helping us create a healthier future for generations to come. Wishing you and your loved ones a joyful, peaceful holiday season and a bright year ahead.

12/18/2025

Our purpose drives our momentum, and Organon teams around the world took meaningful actions and celebrated our progress. We’re energized to carry this momentum into 2026 – staying focused on what matters most: our commitment to delivering impactful medicines and solutions for a healthier every day. 🌍✨

Organon Latam won the ‘best innovation in advertising’ award in the SaludFestival for it’s We Accelerate Action to Celebrate your Future campaign, launched on International Women’s Day. What if we could meet our future selves? This is what four women experienced, with the help of artificial intelligence, who discovered that by taking action for their goals, they can achieve them.

Organon Egypt participated in the Population, Health & Development Conference , where we moderated a panel on building universal and inclusive social protection systems to advance economic justice, women’s health, and human development. We also contributed to another panel, sharing our expertise on how social determinants impact disease burden and health outcomes.

Organon South Africa convened with key partners for the Uganda Workshop on Sustainable Financing for Women’s Health, exploring innovative, home-grown approaches to financing women’s health and advancing sexual and reproductive health (SRH) outcomes that can strengthen Uganda’s SRH ecosystem and support the government’s long-term vision for women’s health.

Organon Korea and the Women's Leaders Network co-hosted the '8th Future Women's Economic Forum' and discussed ways to expand the social and economic roles of middle-aged women and improve their health.

Organon Northwest Europe the Cramlington manufacturing site in Northeast England proudly celebrated its 50 anniversary. This leading hub for solid dose tablet manufacturing supplies over 3 billion tablets to 140 countries each year.

At our newly acquired product site in Oss, Netherlands, we unveiled our latest mural symbolizing our commitment to supporting families on their fertility journeys, continuing a tradition across Organon’s production locations.

12/16/2025

At Organon, our end-of-year Founders Forum is more than a town hall—it’s a moment to reflect, celebrate, and look ahead. This year, we spotlighted our biosimilars portfolio, a cornerstone of growth for Organon.

Joe Azzinaro, Global Commercial Lead, Biosimilars, led a dynamic panel discussion with Satbir Kaur, Head of Alliance Management and Integration, and Mike Casia, Interim Head of U.S. Commercial & Government Affairs. Together, they shared insights into how we’re shaping the future of biosimilars:

- Through collaboration and integration with our collaborators, Organon helps expand access to potentially more affordable biosimilar treatments, with the goal of creating more sustainable healthcare systems

- Organon’s strong global commercial capability mixed with localized ex*****on strategy, complements the capabilities of our collaborators’ in the development and manufacturing for biosimilars

- Patients are at the heart of Organon’s mission, and our support programs, where available, help them gain access to Organon’s biosimilar options

We’re proud of the progress we’ve made and energized for what’s ahead. The momentum is clear: we’re .

12/15/2025

Migraine disproportionately affects women and remains widely underdiagnosed and undertreated. At in Lisbon, we spotlighted the need for a differentiated approach to care, including the importance of collaboration between neurologists and gynecologists in addressing the unique hormonal triggers women face.

See the highlights in our official recap, featuring insights from medical experts, Organon’s perspectives, and attendees’ reactions to our virtual reality migraine with aura simulation.

Our commitment is clear: we are working to advance innovative migraine care with both acute and preventive treatment options, supporting women across every stage of life.

European Headache Federation EHF

12/10/2025

can often cause debilitating symptoms that may interrupt an individual’s daily living, including family life, work, education, and relationships. Yet too often it’s dismissed as just a headache.

Miss Understood is shining a light on what living with migraine really means. At Organon, we’re committed to helping people advocate for themselves, have meaningful conversations with their healthcare providers, and provide acute and preventive treatment options.

12/04/2025

For some people, the start of a can include visual changes including seeing spots, flashes, zigzags. These symptoms, often known as , highlight the complex sensory nature of this condition.

The medical community continues to explore ways to support people living with neurological conditions like migraine. As a company focused on women’s health, we prioritize acute and preventative treatments for people who experience migraines.

We look forward to attending this year’s European Headache Federation EHF Congress, where we remain committed to supporting better access to innovative and comprehensive care in migraine.

Address

30 Hudson Street
Jersey City, NJ
07302

Website

http://www.organon.com/

Alerts

Be the first to know and let us send you an email when Organon posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Organon:

Shortcuts

Want your practice to be the top-listed Clinic in Jersey City?